Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;16(14):899-909.
doi: 10.2217/fon-2020-0094. Epub 2020 Apr 9.

Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases

Alexandra S Zimmer  1 , Seth M Steinberg  2 , Dee Dee Smart  3 , Mark R Gilbert  4 , Terri S Armstrong  4 , Eric Burton  4 , Nicole Houston  1 , Nadia Biassou  5 , Brunilde Gril  1 , Priscilla K Brastianos  6 , Scott Carter  7 , David Lyden  8 , Stanley Lipkowitz  1 , Patricia S Steeg  1
Affiliations

Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases

Alexandra S Zimmer et al. Future Oncol. 2020 May.

Abstract

Brain metastases occur in up to 25-55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood-brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in murine models of breast cancer. Based on these findings, we initiated a secondary-prevention clinical trial with oral TMZ given to HER2-positive breast cancer patients with brain metastases after recent local treatment in combination with T-DM1 for systemic control of disease. Primary end point is freedom from new brain metastases at 1 year. (NCT03190967).

Keywords: T-DM1; brain metastases; metastatic breast cancer; secondary prevention; temozolomide.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Study schema.
SRS: Stereotactic radiosurgery; T-DM1: aAo-trastuzumab emtansine.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J. Clin. 69(1), 7–34 (2019). - PubMed
    1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system. J. Clin. Oncol. 22(14), 2865–2872 (2004). - PubMed
    1. Arvold ND, Oh KS, Niemierko A. et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res. Treat. 136(1), 153–160 (2012). - PubMed
    1. Kennecke H, Yerushalmi R, Woods R. et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28(20), 3271–3277 (2010). - PubMed
    1. Bendell JC, Domchek SM, Burstein HJ. et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12), 2972–2977 (2003). - PubMed

Publication types

MeSH terms

Associated data